Pacific Biosciences of California, Inc. Deferred Revenue Recognized
Pacific Biosciences of California, Inc. (PACB) reported Deferred Revenue Recognized of $4.80 million for the 3-month period ending 2024-09-30, per its 10-Q filed 2024-11-12.
Financial Statements › Income Statement › Other Income
us-gaap:ContractWithCustomerLiabilityRevenueRecognized · last filed 2024-11-12
- Pacific Biosciences of California, Inc. contract with customer, liability, revenue recognized for the quarter ending 2024-09-30 was $4.80M, a 29.73% increase year-over-year.
- Pacific Biosciences of California, Inc. contract with customer, liability, revenue recognized for the quarter ending 2024-06-30 was $2.30M, a 48.89% decline year-over-year.
- Pacific Biosciences of California, Inc. contract with customer, liability, revenue recognized for the quarter ending 2024-03-31 was $3.20M.
- Pacific Biosciences of California, Inc. contract with customer, liability, revenue recognized for the quarter ending 2023-09-30 was $3.70M.
- Pacific Biosciences of California, Inc. contract with customer, liability, revenue recognized for fiscal 2020 was $8.60M.
| Period end | Contract with Customer, Liability, Revenue Recognized 3 month | Contract with Customer, Liability, Revenue Recognized 6 month | Contract with Customer, Liability, Revenue Recognized 9 month | Contract with Customer, Liability, Revenue Recognized 12 month |
|---|---|---|---|---|
| 2024-09-30 | $4.80M 10-Q · filed 2024-11-12 | $10.20M 10-Q · filed 2024-11-12 | ||
| 2024-06-30 | $2.30M 10-Q · filed 2024-08-09 | $5.50M 10-Q · filed 2024-08-09 | ||
| 2024-03-31 | $3.20M 10-Q · filed 2024-05-09 | |||
| 2023-09-30 | $3.70M 10-Q · filed 2023-11-03 | $11.70M 10-Q · filed 2023-11-03 | ||
| 2023-06-30 | $4.50M 10-Q · filed 2023-08-04 | $8.00M 10-Q · filed 2023-08-04 | ||
| 2022-12-31 | $3.50M 10-Q · filed 2023-05-04 | |||
| 2022-09-30 | $11.50M 10-Q · filed 2022-11-08 | |||
| 2022-06-30 | $9.20M 10-Q · filed 2022-08-08 | |||
| 2021-12-31 | $4.00M 10-Q · filed 2022-05-06 | |||
| 2021-09-30 | $7.40M 10-Q · filed 2021-11-05 | |||
| 2021-06-30 | $5.50M 10-Q · filed 2021-08-06 | |||
| 2021-03-31 | $3.10M 10-Q · filed 2021-05-06 | |||
| 2020-12-31 | $8.60M 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| Nautilus Biotechnology, Inc. (NAUT) | United States | $0.129B | -4.16 |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |
| Precipio, Inc. (PRPO) | United States | $0.043B | -36.70 |
| HARVARD BIOSCIENCE INC (HBIO) | United States | $0.037B | -2.70 |
| Bionano Genomics, Inc. (BNGO) | United States | $0.020B | -0.42 |
| ASTROTECH Corp (ASTC) | United States | $0.013B |